

The FDA just approved the first BCL-2 inhibitor specifically for mantle cell lymphoma, giving patients who've failed multiple treatments a new oral option. Sonrotoclax promises higher potency and fewer headaches than its predecessor venetoclax, but the real test is still ahead.
Imagine you've been through two rounds of cancer treatment. Both failed. Your oncologist is running out of options. Now there's a new pill on the shelf.
The FDA just granted accelerated approval to Beqalzi (sonrotoclax), a next-generation drug for patients with relapsed or refractory mantle cell lymphoma (MCL). It's the first BCL-2 inhibitor specifically approved for this disease. And for a small but desperate group of patients, it could change everything.
MCL is a rare but nasty form of blood cancer. It accounts for roughly 5–7% of all non-Hodgkin lymphomas in the West, which translates to about 4,000–5,000 new cases per year in the U.S. alone.
Most patients respond well to initial treatment. The problem? Relapse is nearly universal. Think of it like patching a leaky roof: the first fix holds for a while, but eventually the water finds a new way in.
When MCL comes back, doctors typically reach for BTK inhibitors (drugs like ibrutinib and zanubrutinib that block a key survival signal in cancer cells). These work reasonably well, with response rates in the 65–85% range. But when BTK inhibitors stop working too, the playbook gets very thin.
CAR-T cell therapy is one option, but it requires specialized centers, weeks of manufacturing time, and patients healthy enough to withstand serious side effects. Many older MCL patients simply don't qualify. That leaves a gap: patients who've exhausted the standard options with nowhere obvious to turn.
Sonrotoclax is designed to fill that gap.
Cancer cells are survival artists. One of their favorite tricks is overproducing a protein called BCL-2, which acts like a bodyguard blocking the cell's self-destruct mechanism. Normally, when a cell is damaged or defective, it triggers apoptosis (programmed cell death). BCL-2 prevents that from happening.
Sonrotoclax belongs to a class of drugs called BH3 mimetics. These molecules sneak past BCL-2's defenses by mimicking the body's own pro-death proteins. They bind to BCL-2, pry the bodyguard away from the door, and let the cancer cell's built-in self-destruct sequence run.

The FDA decides on May 29 whether kids as young as four can trade mealtime insulin needles for an inhaler. If approved, Afrezza would be the first needle-free insulin ever cleared for children, and the clinical data is raising eyebrows for all the right (and a few tricky) reasons.


Join thousands of biotech professionals who start their day with our free, daily briefing.
If that sounds familiar, it should. Venetoclax, made by AbbVie and Roche, pioneered this approach years ago and became a blockbuster in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). But venetoclax was never formally approved for MCL, and it has some well-known headaches.
Sonrotoclax, developed by BeiGene (marketed through its BeOne Medicines arm), was engineered to be the upgrade.
Venetoclax changed hematologic oncology. But it's not perfect.
Its biggest clinical hassle is tumor lysis syndrome (TLS), a potentially life-threatening condition where dying cancer cells dump their contents into the bloodstream all at once. Think of it like demolishing a building without clearing the debris: the rubble can overwhelm the city's infrastructure. Venetoclax patients often need hospital monitoring during their first doses.
Then there's resistance. Cancer cells eventually learn to dodge venetoclax, most commonly through a mutation called G101V that weakens the drug's grip on BCL-2.
Sonrotoclax attacks both problems. In lab studies, it binds to BCL-2 with roughly 20-fold higher affinity than venetoclax, using a different angle of attack on the protein's surface. That alternative binding mode means it retains activity against the G101V mutation that renders venetoclax ineffective. Its half-life is also much shorter (about 4 hours versus venetoclax's 26), which gives doctors a faster "off switch" if toxicity becomes an issue.
In the pivotal trial, TLS occurred in 7% of the MCL safety population, including two clinical TLS cases and six laboratory TLS cases, all reversible.
The FDA based its decision on a Phase 1/2 trial called BGB-11417-201, which enrolled heavily pretreated MCL patients. All 103 patients in the efficacy group had previously received both a BTK inhibitor and anti-CD20 therapy. The median patient had gone through three prior lines of treatment.
The headline result: an overall response rate of 52%, with about 16% of patients achieving a complete response (meaning no detectable cancer on scans). Responses came fast, too, with a median time to response of just 1.9 months.
More importantly, those responses lasted. The median duration of response hit 15.8 months, a meaningful number for patients who've already failed multiple treatments.
Now, 52% might not sound like a home run. But context matters. These are patients at the end of the line, with aggressive disease that has already beaten several therapies. In that population, a response rate north of 50% with durable remissions is clinically significant.
One encouraging subgroup finding: patients treated after fewer than three prior lines saw an ORR of 61%, hinting that earlier use could yield even better results.
Sonrotoclax isn't without risks. Serious adverse reactions occurred in 37% of patients, with pneumonia being the most common (10%). Neutropenia (dangerously low white blood cell counts) and other infections are real concerns. Patients need regular blood monitoring, and the drug requires a four-week dose ramp-up to minimize TLS risk before settling into its maintenance dose of 320 mg once daily.
The approval itself comes with an asterisk. "Accelerated approval" means the FDA was convinced enough by the response rate data to let the drug reach patients quickly, but BeiGene still needs to prove it actually helps patients live longer. That confirmation is expected from CELESTIAL-RRMCL, a Phase 3 trial comparing sonrotoclax plus zanubrutinib against zanubrutinib alone in relapsed MCL.
This approval matters beyond the roughly 4,000 MCL patients diagnosed each year. Sonrotoclax is the opening act for what analysts are calling a second wave of BCL-2 inhibitors. BeiGene is also running late-stage trials in CLL, where venetoclax has dominated for years. Other companies (Ascentage Pharma with lisaftoclax, InnoCare with ICP-248) are right behind.
For now, venetoclax's throne is safe in CLL and AML. But in MCL, sonrotoclax essentially created a new labeled market where venetoclax never formally existed. It's the first BCL-2 inhibitor with a specific MCL indication, and for community oncologists looking for an oral option before referring patients to CAR-T centers, it's an attractive addition to the toolkit.
The real test comes next: can sonrotoclax prove it extends survival, not just shrinks tumors? If the Phase 3 data deliver, this little pill could reshape how doctors think about lymphoma treatment from the second line onward.
A Paragon Biosciences spinout just raised $290 million to go after migraine prevention with a totally different approach. The bet: current drugs leave half of patients undertreated, and a protein called PACAP could be the missing piece.